STING1 and neoplasm: Combination therapy activates antitumor NK-cell response in MHC-I+/STINGlow (4T1) tumors, whereas in MHC I-deficient/STINGhigh (B16-F10) tumors, STING agonist as monotherapy provides sufficient anti-tumor NK cells response.